Literature DB >> 22495452

Multiple microsurgical resections for repeated recurrence of glioblastoma multiforme.

Bujung Hong1, Bettina Wiese, Michael Bremer, Hans E Heissler, Fedor Heidenreich, Joachim K Krauss, Makoto Nakamura.   

Abstract

OBJECTIVES: There has been little evidence so far supporting further surgical intervention in case of repeated recurrence of glioblastoma multiforme (GBM). Thus, the efficacy and utility of repeated resection remains unclear but worthy of consideration. The aim of this study was to review the efficacy of multiple repeated resections in patients with recurrent GBM.
METHODS: Forty-two patients underwent repeated surgical resections for recurrent GBM. All patients who underwent >2 surgical interventions were clustered in group A. Group B were patients treated nonsurgically after resection of the first recurrence. Patients' treatment history, including surgical interventions, radiotherapy, chemotherapy regimens, postoperative complications, Karnofsky Performance Score, and survival rate were reviewed.
RESULTS: Group A consisted of 10 patients (median age, 60.5 y) and group B of 32 patients (median age, 56.5 y). Histopathologic findings revealed typical GBM in 8 patients of group A and in 23 patients of group B. An oligodendroglial component was detected in 2 patients of group A and in 7 patients of group B. The median Karnofsky Performance Score after the first surgery for tumor recurrence was 80 in both groups (P=0.084). The median overall survival time was 26 months in patients of group A and 16 months in patients of group B (P=0.052). The 2-year survival rate of group A was 58.3% and significantly higher than in group B (29.0%; P=0.036). The 3-year survival rate of group A was 31.1% and 12.4% of group B (P=0.038).
CONCLUSIONS: Microsurgical resection of repeatedly recurring GBM is likely to prolong survival. Repeated surgical resection may be considered as an effective treatment option in addition to radiochemotherapy in repeated GBM recurrence.

Entities:  

Mesh:

Year:  2013        PMID: 22495452     DOI: 10.1097/COC.0b013e3182467bb1

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  14 in total

1.  Benefit of tumor resection for recurrent glioblastoma.

Authors:  Johanna Quick; Florian Gessler; Stephan Dützmann; Elke Hattingen; Patrick N Harter; Lutz M Weise; Kea Franz; Volker Seifert; Christian Senft
Journal:  J Neurooncol       Date:  2014-02-15       Impact factor: 4.130

2.  Feasibility of fluorescence-guided resection of recurrent gliomas using five-aminolevulinic acid: retrospective analysis of surgical and neurological outcome in 58 patients.

Authors:  Anne-Katrin Hickmann; Minou Nadji-Ohl; Nikolai J Hopf
Journal:  J Neurooncol       Date:  2015-01-04       Impact factor: 4.130

Review 3.  Treatment options for progression or recurrence of glioblastoma: a network meta-analysis.

Authors:  Catherine McBain; Theresa A Lawrie; Ewelina Rogozińska; Ashleigh Kernohan; Tomos Robinson; Sarah Jefferies
Journal:  Cochrane Database Syst Rev       Date:  2021-05-04

Review 4.  Treating recurrent glioblastoma: an update.

Authors:  Carlos Kamiya-Matsuoka; Mark R Gilbert
Journal:  CNS Oncol       Date:  2015

5.  Strategies of eradicating glioma cells: a multi-scale mathematical model with MiR-451-AMPK-mTOR control.

Authors:  Yangjin Kim; Gibin Powathil; Hyunji Kang; Dumitru Trucu; Hyeongi Kim; Sean Lawler; Mark Chaplain
Journal:  PLoS One       Date:  2015-01-28       Impact factor: 3.240

6.  MicroRNA-101 inhibits proliferation, migration and invasion of human glioblastoma by targeting SOX9.

Authors:  Nan Liu; Lei Zhang; Zhen Wang; Yingduan Cheng; Pengxing Zhang; Xin Wang; Weihong Wen; Hongwei Yang; Hui Liu; Weilin Jin; Yongsheng Zhang; Yanyang Tu
Journal:  Oncotarget       Date:  2017-03-21

7.  5-Aminolevulinic acid-guided resection improves the overall survival of patients with glioblastoma-a comparative cohort study of 343 patients.

Authors:  Asfand Baig Mirza; Ioannis Christodoulides; Jose Pedro Lavrador; Anastasios Giamouriadis; Amisha Vastani; Timothy Boardman; Razna Ahmed; Irena Norman; Christopher Murphy; Sharmila Devi; Francesco Vergani; Richard Gullan; Ranjeev Bhangoo; Keyoumars Ashkan
Journal:  Neurooncol Adv       Date:  2021-03-26

8.  Regulation of cell proliferation and migration in glioblastoma: new therapeutic approach.

Authors:  Yangjin Kim
Journal:  Front Oncol       Date:  2013-03-18       Impact factor: 6.244

9.  mir-218-2 promotes glioblastomas growth, invasion and drug resistance by targeting CDC27.

Authors:  Zhuoying Feng; Luping Zhang; Junchen Zhou; Shuai Zhou; Li Li; Xuyan Guo; Guoying Feng; Ze Ma; Wenhua Huang; Fei Huang
Journal:  Oncotarget       Date:  2017-01-24

10.  Challenges in cerebrospinal fluid shunting in patients with glioblastoma.

Authors:  Bujung Hong; Manolis Polemikos; Hans E Heissler; Christian Hartmann; Makoto Nakamura; Joachim K Krauss
Journal:  Fluids Barriers CNS       Date:  2018-06-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.